Open AccessManagement of Children with Psoriasis During the COVID-19 Pandemic
Author(s) -
Н. Н. Мурашкин,
А. И. Материкин,
Э. Т. Амбарчян,
Р. В. Епишев,
Leonid A. Opryatin,
Р. А. Иванов
Publication year - 2021
Publication title -
voprosy sovremennoj pediatrii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.12
H-Index - 5
eISSN - 1682-5535
pISSN - 1682-5527
DOI - 10.15690/vsp.v20i5.2321
Subject(s) - psoriasis , pandemic , medicine , covid-19 , proinflammatory cytokine , disease , pathogenesis , immunology , inflammation , infectious disease (medical specialty)
The spread of new coronavirus infection (COVID-19) changes specialists' approaches to patients with chronic diseases, including those with chronic dermatoses. The high risk of COVID-19 complications in patients with psoriasis is connected to the features of disease pathogenesis (such as high activity of proinflammatory cytokines) and used immunosuppressive therapy. Psoriasis affects up to 1% of children in Europe, while 10-20% of them have moderate or severe form of disease. These children may require immunosuppressive treatment, including genetically engineered biological therapy. There is only limited data on adults and children with psoriasis during the COVID-19 pandemic.